GB-5267 (MUC16 CAR T)
Generate:Biomedicines (trial sponsor Roswell Park): company profile
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
GB-5267 is a MUC16 CAR T from Generate:Biomedicines (trial sponsor Roswell Park). The source describes it as cell therapy (CAR T). It is being developed for platinum-resistant ovarian cancer. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT07489287. The AI role named in the source is protein design. Registry records: NCT07489287, Phase 1, recruiting, updated Oct 22, 2026. About the company, based in United States: Flagship-founded generative biology platform that designs protein therapeutics computationally; lead asset GB-0895 (anti-TSLP, golukibart) is in Phase 3 for severe asthma. First patient dosed. The latest dated source is from Oct 1, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Generate:Biomedicines (trial sponsor Roswell Park)
- Indication
- Platinum-resistant ovarian cancer
- Therapeutic area
- Oncology
- Modality
- Cell therapy (CAR T)
- AI role
- Protein design
- Phase in the source
- Phase 1, as of Oct 1, 2026
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
First patient dosed
AI evidence
AI source: Company
“GB-5267 was engineered by Generate with AI through the design and evaluation of CAR architectures at scale”
Trial records
- NCT07489287 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
Official X post: Phase 1
First patient dosed
-
Registry check
Registry sponsor Roswell Park.
-
NCT07489287 record updated
Phase 1, Recruiting
About Generate:Biomedicines
Flagship-founded generative biology platform that designs protein therapeutics computationally; lead asset GB-0895 (anti-TSLP, golukibart) is in Phase 3 for severe asthma.
Spot an error? Tell me and I'll fix it.